SCHEMBL1998366

SCHEMBL1998366

COc1ccc2c(c1)c(C(=O)c1ccn(-c3ccncc3)n1)cn2Cc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 3/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
AHR P35869 1/20 0.44
KCNA3 P22001 1/20 0.43
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13229023 0.92 LMNA (0.48) LMNAALDH1A1SMN1; SMN2HDAC1HDAC2
SCHEMBL1999497 0.92 LMNA (0.56) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2003033 0.91 LMNA (0.47) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2000664 0.90 LMNA (0.48) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2008252 0.88 LMNA (0.46) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2007990 0.88 LMNA (0.51) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2004843 0.88 LMNA (0.48) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2008651 0.86 LMNA (0.46) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2004180 0.85 LMNA (0.51) LMNAALDH1A1SMN1; SMN2MAPTHDAC1
SCHEMBL2003746 0.84 LMNA (0.48) LMNAALDH1A1SMN1; SMN2MAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT LMNA 4536/4885ALDH1A1 178/4885SMN1; SMN2 4663/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 LMNA 4089/4885ALDH1A1 648/4885SMN1; SMN2 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.